11/07/2013 18:45:00

U.K. Recalls Drugs Made in India

LONDON--In another sign of possible manufacturing problems in India's pharmaceutical industry, the U.K.'s medicines regulator said it was recalling 16 drugs made by Wockhardt Ltd. (532300.BY) after finding "manufacturing deficiencies" at one of the company's factories in India.

The Medicines and Healthcare products Regulatory Agency, or MHRA, called it a "precautionary recall," as there is no evidence that the medicines are defective. The agency said it is recalling the drugs from pharmacies and wholesalers but isn't asking patients to return their Wockhardt medicines.

"There is no evidence of a patient safety risk. ...however, the MHRA has to act in the interest of public health as poor manufacturing standards cannot be allowed to continue," the agency said.

The recalled drugs, manufactured in the central Indian city of Waluj, include treatments for infections, hypertension, diabetes, epilepsy and other diseases. The MHRA said the plant suffered from "poor cleaning practices" and defective ventilation systems. The agency inspection also found evidence of "forged documents relating to staff training records."

In an emailed statement, Wockhardt confirmed the news and said the recall would result in a one-time charge of 1.5 million pounds ($2.25 million) this year. Exports from the Waluj plant constitute less than 5% of the company's total U.K. sales and less than 2% of overall sales, it added.

It was the second recent setback for the company and its Waluj factory. In May, the U.S. Food and Drug Administration imposed an import ban on products from the factory after it failed an FDA safety inspection. The FDA didn't elaborate on the problems it found.

In a conference call at the time, Wockhardt Chairman Habil Khorakiwala said the company was implementing "corrective measures to be in compliance with the FDA guidelines." He said the U.S. import ban could cost the company $100 million in revenue this fiscal year. Wockhardt generated total revenue of 25.6 billion rupees ($460.6 million) in the year ended March 31, 2012.

Also in May, India's Ranbaxy Laboratories Ltd. (500359.BY) agreed to pay $500 million in civil and criminal fines for exporting adulterated drugs to the U.S.

In a phone interview Thursday, D.G. Shah, secretary-general of the Indian Pharmaceutical Alliance, an industry body, said the group has written to the FDA asking it to conduct workshops with Indian companies to correct erroneous practices.

"Companies need to better understand FDA processes, and there needs to be a correction in their organizational culture, right from drug discovery to development and production," Mr. Shah said.

Write to Jeanne Whalen at jeanne.whalen@wsj.com and Anirban Chowdhury at anirban.chowdhury@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 11, 2013 13:45 ET (17:45 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
08 Feb
OMXC20
      På en dag som i dag med kursfald på +5% er det ekstra vigtigt at tænke og handle rationelt. He..
52
05 Feb
OMXC20
  Inden jeg starter med at forklare, hvad det er der aktuelt sker på aktiemarkedet, vil jeg henvise ..
26
05 Feb
 
    En lærerinde i 3. klasse stillede sine elever det evigt relevante spørgsmål:"Hvad vil du gerne..
23
10 Feb
FING-B
lhome .... (16.08) .....   Du skal være klar over at du har gang i at overveje een af de mest volati..
20
09 Feb
OMXC20CAP
Det er egentlig ganske morsomt. Men et menneskeligt træk, især blandt handyr af racen, er ofte, at m..
19
09 Feb
OMXC20
skal man  ikke sælge - men vælge det rigtige tidspunkt at købe - om det er i dag, er svært at foruds..
15
07 Feb
ZEAL
Jeg har set lidt på de patent sagerne som køre mellem AstraZeneca, Sanofi og TEVA omkring GLP-1'er. ..
15
11 Feb
ABIRUS
Den største trussel mod europa er europas egne elendige politikere. De mangler mod, visioner og miss..
14
05 Feb
NOVO-B
Købte NN i kurs 247,60 i 2014. Solgte i december 2015 i kurs 293,20. Købte Danske Bank i januar i ku..
14
05 Feb
FING-B
Vi 8 har snakket med flere analysefirmaer i dag som jeg ikke lige kan huske navnene på, og de fortæl..
14

Form 8.3 - BG Group Plc

10/02/2016 15:29:02
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Form 8.3 - Just Retirement Group Plc

10/02/2016 12:57:16
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Form 8.3 - Home Retail Group

10/02/2016 10:58:35
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Ubisoft® reports third-quarter 2015-16 sales
2
Bottomline Technologies Announces Next Generation Healthcare Privacy and Data Security Solution
3
CORRECTION: L'Oréal: News Release: "2015 Annual Results"
4
Belships ASA : Report 4th quarter 2015
5
L'Oréal: News Release: "2015 Annual Results"

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
12 February 2016 07:39:34
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20160211.1 - EUROWEB7 - 2016-02-12 08:39:34 - 2016-02-12 07:39:34 - 1000 - Website: OKAY